Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 7;9(1):e723.
doi: 10.1002/ams2.723. eCollection 2022 Jan-Dec.

Clinical application of skin antisepsis using aqueous olanexidine: a scoping review

Yutaro Shinzato  1 , Eiryu Sakihara  1 , Yuki Kishihara  1 , Masahiro Kashiura  1 , Hideto Yasuda  1 , Takashi Moriya  1
Affiliations

Clinical application of skin antisepsis using aqueous olanexidine: a scoping review

Yutaro Shinzato et al. Acute Med Surg. .

Abstract

Surgical site infections (SSIs) and catheter-related bloodstream infections (CRBSIs) caused by bacteria from surfaces poorly disinfected with chlorhexidine gluconate (CHG) and povidone-iodine (PVP-I) are increasing. Olanexidine gluconate (OLG) was developed in 2015 in Japan to prevent SSI and CRBSI caused by bacteria resistant to CHG and PVP-I. This scoping review aimed to identify the knowledge gap between what is known and what is not known about the disinfection efficacy of OLG. We searched MEDLINE through PubMed, the Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the International Clinical Trials Registry Platform search database, ClinicalTrials.gov, and the Web-based database of Japanese medical articles for works published to July 18, 2021. Manual reference searches were also carried out. A total of 131 studies were screened. Forty-seven studies were included in this review and classified into two major categories: studies on pharmacological effects and spectrum (n = 29) and studies on clinical and adverse effects (n = 18). Olanexidine gluconate showed bactericidal activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, in addition to common Gram-positive and Gram-negative bacteria. In clinical settings, although there is limited evidence on SSI prevention, 1.5% OLG might be more effective than 10% PVP-I and 1% CHG in preventing SSI. However, the clinical usefulness of OLG is unclear due to the limited number of clinical studies. Also, clinical research is limited to studies targeting SSI prevention, and there are no clinical studies on CRBSI. Further clinical studies are needed on SSI and CRBSI prevention.

Keywords: Catheter‐related bloodstream infection; olanexidine; scoping review; skin antiseptic solution; surgical site infection.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Flowchart of study screening and inclusion in the present scoping review of studies regarding the clinical application of skin antisepsis using olanexidine. CINAHL, Cumulative Index to Nursing and Allied Health Literature; ICTRP, International Clinical Trials Registry Platform.
Fig 2
Fig 2
Chemical structure of olanexidine.
See this image and copyright information in PMC

References

    1. Kashimura N, Kusachi S, Konishi T et al. Impact of surgical site infection after colorectal surgery on hospital stay and medical expenditure in Japan. Surg. Today 2012; 42: 639–45. - PubMed
    1. Nakamura I, Fukushima S, Hayakawa T, Sekiya K, Matsumoto T. The additional costs of catheter‐related bloodstream infections in intensive care units. Am. J. Infect. Control 2015; 43: 1046–9. - PubMed
    1. Blot SI, Depuydt P, Annemans L et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter‐related bloodstream infections. Clin. Infect. Dis. 2005; 41: 1591–8. - PubMed
    1. Rosenthal VD, Guzman S, Migone O, Crnich CJ. The attributable cost, length of hospital stay, and mortality of central line‐associated bloodstream infection in intensive care departments in Argentina: A prospective, matched analysis. Am. J. Infect. Control 2003; 31: 475–80. - PubMed
    1. Berríos‐Torres SI, Umscheid CA, Bratzler DW et al. Centers for disease control and prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. 2017; 152: 784–91. - PubMed

Publication types

LinkOut - more resources